Welcome To Paragon Ventures
|
We hope this note finds you safe and well as the world begins to breath a bit easier as the challenges of a pandemic subside. As our businesses are all on the front lines of healthcare and life sciences we continue to be honored (and amazed) by the spirit and dedication to succeed during these trying times.
We are pleased to report that through April 2021, Paragon Ventures closed a record number and breadth of transactions through the pandemic. Collectively, our clients represented over $165MM in revenues and a broad base of care initiatives.
Inside this edition, we have a healthy selection of new acquisitions opportunities across several healthcare sectors. From healthy living products to biologic therapies we have something of beauty across the continuum of care. We also have included some insight into the changing capital gains taxes predicted for the years ahead. We encourage you to read this and assess its impact for your specific business valuation and potential net proceeds in a transaction.
If the time is right for you and your business, the healthcare M&A markets are strong and some sectors offering unprecedented valuations and options for management through a strategic transaction. As always we welcome your inquires and continue to hold all discussions strictly confidential. Text Link
|
|
Biden Tax Plan May Impact Long Term Capital Gains
|
|
President Biden has formally announced his plans to increase the long-term capital gains tax rate from 20% to 39.6%. Many business owners are looking to accelerate deal transactions before a new rate is implemented. Are you looking to complete a deal quickly? Our process is quick and easy, and there is still time to consummate a transaction in 2021. Contact Paragon Ventures for more information.
|
|
Implications for Timing and Sale of your Business
|
You have a solid, stable business you’ve built for years, maybe decades. The business is humming along, and you feel you’re not quite ready to sell or retire, perhaps that is still a year or two out in your mind. Have you considered the implications of a new tax regime on the net proceeds of a sale?
Under a new tax regime, you may need a 26% higher EBITDA sale multiple, or 26% greater EBITDA, to generate the same net proceeds. That’s like working nine whole months for free, just to pay the increase in taxes.
An Example:
Let’s say a Company has a two-million-dollar EBITDA, and sells its stock for $10 million, or a 5x multiple. The basis in the stock in this example is $2 million and capital gain would be $8 million. (Asset sales would be treated slightly differently, I will discuss further below.)
Current tax code allows for long-term capital gains to be taxed at 20%, resulting in net proceeds of $8.4 million.
The Biden campaign proposes rolling back Trump administration marginal rates “to historical levels”, and “taxing investment gains the same as earned income”. Haven’t heard this? It’s buried, but you’ll find the reference in the Biden plan here: https://joebiden.com/wp-content/uploads/2020/08/UNITY-TASK-FORCE-RECOMMENDATIONS.pdf on page 15: “A guiding principle across our tax agenda is that the wealthiest Americans can shoulder more of the tax burden, including in particular by making investors pay the same tax rates as workers…” That signals a top marginal rate of 39.6% for both earned and investment income, i.e., the sale of your business. In this scenario, the tax on the sale is nearly doubled, reducing net proceeds by more than $1.5 million to $6.8 million, down from $8.4 million.
That’s like working nine whole months for free, just to pay the increase in taxes.
In order to net the same proceeds as a sale at current tax rates, the Company would need to grow EBITDA by 26% to $2.52 million, or achieve a sale multiple 26% higher, roughly 6.3X EBITDA. It’s doubtful a buyer would be willing to absorb your tax problem through increased purchase price…they will have their own tax problems.
Think this is far fetched? Perhaps. 25% to 35% would be more in line with historical norms. But consider that long term capital gains rates have been higher than 20% more often than they’ve been 20% or lower. Even a 5% increase in our example is $400,000 more tax.
|
|
|
|
Every company is different, and every industry segment is different. The urgency to take advantage of current favorable rates is most relevant to company owners looking to sell in the next year or two anyway, and whose business is relatively flat in terms of earnings growth. if you have consistent 20% or better earnings growth and / or a longer time horizon, your ultimate net proceeds should outpace a tax increase. Perhaps.
Asset sales will face similar consequences if the depreciation recapture rate increases from the current 25% to ordinary income levels.
Please consult your tax advisor on circumstances specific to your business, and reach out to us at Paragon to discuss your exit goals and recent activity in your market segment. Paragon Ventures does not provide tax advice, this is only an illustration for you to consider timing of a sale. Paragon Ventures has no political motive in this discussion, our goal is to present the implication of a capital gains tax change to net proceeds, in alignment with our decades-long mission to get the best outcomes for our clients.
Paragon Ventures is one of the nation’s leading specialists in the merger, acquisition, and divestiture of private mid-market companies. As an intermediary with experience and expertise, we can facilitate the entire process of buying or selling a business. We specialize in the healthcare and life sciences industries including all sectors of pharmacy distribution, home healthcare, respiratory care, infusion therapies, sleep therapy, nursing services, behavioral health, hospice, medical supply, medical device and related medical technologies.
The M&A activity across healthcare sectors continue to drive strong valuation and strategic options for business owners. Considering a sale, merger or recapitalization? If your business is ready, the market opportunities and strategic options in the current market are worthy of your consideration.
|
|
|
|
For more information contact Paragon Ventures
800-719-1555 Ext. 209 or 415-786-8153 (cell)
|
|
AVAILABLE FOR ACQUISITION
|
|
Listing Number - MA320-20020
Revenue Size - 22.67 MM
|
|
Click below for a Profile At A Glance on this opportunity
For more information contact Paragon Ventures
800-719-1555 Ext. 205 or 603-661-7188 (cell)
|
|
AVAILABLE FOR ACQUISITION
|
|
Listing Number - SC321-20025
Revenue Size - 20.7 MM
|
|
Click below for a Profile At A Glance on this opportunity
For more information contact Paragon Ventures
Call: 800-719-1555 Ext. 203 or 215-356-8003 (cell)
|
|
When The Time Is Right...
Paragon Ventures
|
|
AVAILABLE FOR ACQUISITION
|
|
Long Term Care Nurse Staffing
Listing Number - SE320-20015
Revenue Size - 15 MM
|
|
Click below for a Profile At A Glance on this opportunity
For more information contact Paragon Ventures
Call: 800-719-1555 Ext. 203 or 215-356-8003 (cell)
|
|
AVAILABLE FOR ACQUISITION
|
|
Listing Number - NE218-35010
Revenue Size - 35MM
|
|
Click below for a Profile At A Glance on this opportunity
For more information contact Paragon Ventures
Call: 800-719-1555 Ext. 206 or 315-559-3140 (cell)
|
|
AVAILABLE FOR ACQUISITION
|
|
Skin Care: Aesthetic Device Manufacturer / Distributor
Listing Number - US321-08016
Revenue Size - 8 MM
|
|
Click below for a Profile At A Glance on this opportunity
For more information contact Paragon Ventures
800-719-1555 Ext. 205 or 603-661-7188 (cell)
|
|
AVAILABLE FOR ACQUISITION
|
|
Natural Health Products Manufacturer & Distributor
Listing Number - MA320-15010
Revenue Size - 2 MM
|
|
Available for acquisition is a Natural Products Company that designs, manufactures, and markets products that Relieve Symptoms, Fix the Ailment and Facilitate Repair. Substantial time and effort in the business model has produced significant market penetration and profit, year after year.
A new owner of this business will benefit immediately from a substantial cash flow allowing for future initiatives including new product development, market expansion, increased distribution opportunities and greater presence among end users. Steady revenue growth with sales of $2.0mm and a healthy EBIDTA of $898k. All operational systems are in place for an easy transition to new ownership. The founder will provide transitional services including at buyer’s option, to continue to be involved in new product development, product research and clinical oversight.
|
|
For more information,
Contact Tony Marsallo
Call: 800-719-1555, Ext 209 or (315) 559-3140 (mobile)
|
|
AVAILABLE FOR ACQUISITION
|
|
Hi-Tech Respiratory Equipment Rental Company
Listing Number - MA220-06514
Revenue Size - 6.5 MM
|
|
Available for acquisition is a business-to-business provider of medical equipment rental service to hospitals, long term care providers, respiratory rehab and home healthcare. The business is renowned for its biomedical equipment expertise and high-quality service. All equipment is provided patient ready and delivery services available 365 days 24/7. This enables its caregiver customers to focus on the clinical needs of their patients without the burden and expense of ownership and maintenance of the equipment.
|
|
The Company serves as a vital resource to its customers by offering to meet their biomedical equipment needs on an as needed basis and thus more effectively manage their scarce capital. As the healthcare industry continues to be challenged by increasing demand with declining reimbursements, providers are becoming increasingly aware that the true costs of capital equipment include more than the fixed cost of acquisition. Periodic maintenance requirements, repair costs, logistics and asset management, continue to contribute to expenses even as utilization fluctuates. The option of biomedical equipment rental turns these fixed costs into variable expense tied to actual utilization needs.
Click below for full profile
|
|
For more information contact Paragon Ventures
Jonathan Sadock
|
|
AVAILABLE FOR ACQUISITION
|
|
Full Line Medical Supply Distributor
Listing Number - MW314-06003
Revenue Size - 15.5 MM
|
|
Strategically, the Company has developed many successful programs over the years to sell to healthcare professionals and consumers. They have utilized various channels such as outside and inside sales representatives, direct to consumer and health care professionals, and through on-line platforms. One distinct opportunity the company recognized was the growing use of on-line ordering.
The Company had developed different avenues through which a customer can order; such as use of ordering guides telephonically, their online store or other online platforms such as Amazon. Although consumers order through the platform company, the Company is the fulfilment center and successfully secures repeat orders as a result of their strong ratings. The Company consistently monitors its products sold through the platform channels to ensure profitability margins are maintained.
Additionally, the Company offers specialty packaged items that are exclusive. Recognizing the increase in out of pockets payments due high deductible insurance plans, the Company leveraged its buying power to offer competitive pricing to meet that market need. The Company does not currently bill third party payors which offers an opportunity for future revenue growth outside its current strategic focus.
|
|
For more information contact Paragon Ventures
800-719-1555 Ext. 205 or 603-661-7188 (cell)
|
|
AVAILABLE FOR ACQUISITION
|
|
International Patented Medical Device Manufacturer, Distributor
Listing Number - EU319-14600
Revenue Size - 1.3 MM
|
|
For more information,
Contact Tony Marsallo
Call: 800-719-1555, Ext 209 or (315) 559-3140 (mobile)
|
|
AVAILABLE FOR ACQUISITION
|
|
Medical Cardiology Supply Specialists - Kitting Manufacturer
Listing Number - NE319-04025
Revenue Size - 4.8 MM
|
|
Cardiology focused Medical Supply Business with an extensive inventory of cardiology equipment and supplies selling to hospitals, medical offices and medical supply companies. In addition to supplying the most respected, major brands in cardiology, the Company is a manufacturer of custom kits for cardiology event recording and testing. The Company is a leading supplier for cardiology providers including echo/ultrasound, cardiac testing and monitoring equipment and supplies. The Company serves thousands of of medical professionals and their patients in the United States and globally.
For the trailing twelve months ending January 2021 the business generated $4.8MM and generated $775,000 EBITDA. The business is well positioned for continued growth and expansion. Additional information is available to qualified buyers.
|
|
For more information,
Contact Tony Marsallo
Call: 800-719-1555, Ext 209 or (315) 559-3140 (mobile)
|
|
AVAILABLE FOR ACQUISITION
|
|
Licenses Caregiver Registry
Listing Number - NE320-01025
Revenue Size - 1.1 MM
|
|
For more information,
Contact Tony Marsallo
Call: 800-719-1555, Ext 209 or (315) 559-3140 (mobile)
|
|
Dollars & Sense on Valuations
|
|
Valuation has always been a pivotal factor in a business owner’s decision to sell. There are frequently additional motivating factors such as retirement, health, business opportunities, stress, and a variety of others, but they are usually coupled with an ability to obtain the right price and terms for the business.
At no cost or obligation, we provide an analysis on the business that covers value and other market realities so you understand how much your business is worth in the current market. We do this to help a business owner to make informed decisions before making any commitments to market and sell their business. Click here to read more of this article...
|
|
AVAILABLE FOR ACQUISITION
|
|
Medical Supply, Ostomy, Urological, Incontinence
Patient Care Products
Revenue: $5.6MM - EBITDA: $833K
|
|
Available for acquisition is a ostomy, urological, incontinence, patient care products and services provider with strong contract relationships and diverse payor mixes. The company provides the services and supplies to patients in their homes and at the company stores. The Company’s staff include highly trained and experienced homecare professionals including licensed prosthetic/orthotic fitters and technicians that serve the Companies growing patient population.
The Company’s long time market presence coupled with a favorable product mix drive strong margins and sustainable EBITDA. Over the trailing twelve months ended Dec 2020, the business has generated gross revenues of $ 5.67MM with an adjusted EBITDA of $ 833K. The Company continues to grow with solid contracts, referral relationships and a tremendous history of excellent service.
|
|
For more information,
Contact Scott Fife
Call: 800-719-1555, Ext 203 or (215) 356-8003 (mobile)
|
|
Note: Search Funds & Unfunded Sponsors: Our clients will not process NDAs or accept offers from such groups until financial pre-qualifications are met. Proof of funds will be required before any letter of intent or offer to purchase will be considered from unfunded prospective buyers, i.e., independent sponsors, search funds, fund-less sponsors. An Earnest Deposit held in escrow may also be required.
|
|
The Paragon Ventures Market Pulse website provides insight into healthcare mergers and acquisitions processes and notable completed transactions across many sectors. Out team is in market discussions with active buyers and investors across the continuum of care. We use this information to provide strategic insights into successful transactions across the healthcare and life sciences sectors.
https://www.paragonventures.com/market-pulse-posts/
This information has been compiled from publicly available press releases and Paragon Ventures market research activities. This information has been compiled with publicly available information. Contact us for more information and insights into the strategic options available for your business in the current market.
|
|
Paragon Ventures is pleased to announce the sale of its client, Aircare Medical to Lincare.
THE BUYER
Lincare is an national leader providing respiratory and medical supplies to patients throughout the United States.
THE SELLER
Aircare Medical SMRT Sleep is a provider of respiratory and CPAP supplies.
If you would like more information about this transaction or Paragon Ventures contact Scott Fife, Vice President at 215-356-8003 or via email at sfife@paragonventures.com
|
|
Below are requests we have received from prequalified prospective buyers and investors. They reflect a small portion of the requests we receive on a daily basis.
|
|
May 2021 Buyer & Investor Inquiries
- We are interested in acquiring a Hospice business and operate it under our umbrella Our primary target markets are South and North Carolina, Tennessee, Georgia, Florida, Virginia.
- I'm interested in companies operating in the healthcare RCM space.
- Looking for home health in Dallas area and in Phoenix area.
- Focused predominately on medical devices/technology, outsourced services, multi-site facilities and other near adjacent markets.
- $20MM revenue software, saas, and tech businesses
- Healthcare businesses with at least $3 Million in EBITDA. Perfer businesses with no customer that's comprises more than 10% of revenues
- Manufacturing and essential services in Florida
- Looking for respiratory businesses
- 503A and 503B pharmacies
- home care in palm beach or florida in general
- I need a hme /dme in Nc with uhc, and aetna and humana contracts
- Behavioral Health companies over $3MM revenues (anywhere)
- Looking for a business with highly recurring or repeatable revenue in an industry that is growing. Open to any geographic location. Happy to discuss further criteria.
- We are a family office interested in purchasing hospice businesses in the midwest. We are headquartered in Chicago.
- Orthotics and Prosthetics
- We look for businesses with $1-$5M of EBITDA and highly recurring revenue. We generally prefer services businesses with a focus on equipment maintenance and repair.
- We are a long-term lower middle market investment group based in St. Louis, MO. Transactions typically are in the $5M - $50M of EV range but can go higher or lower for the right opportunity. We are focused on equipment going into medical device, pharmaceutical or laboratory settings. Additionally, anything that touches the testing and validation process, service or equipment, are of interest.
- New England; EBITDA 750K+ or Revenue 3M+ - Ancillary Support Services, Behavioral Health Services, Healthcare Financial Services, Healthcare Provider, Home Health / Hospice, Medical Device, Medical Supply
- Retail pharmacies
- B2B Services such as healthcare or industrial technology/equipment-related services; regulatory compliance software and services; other business service
- EBITDA of $1M to ~$4M annually
- Pharmacies - retail, specialty, 340B
- Skilled Home Health and Hospice; up to $10MM purchase price.
- looking to a acquire a revenue cycle management, medical billing, or medical claims company with revenues greater than $1.0m. We are generally agnostic to geography.
- Acquisition opportunities in the pharmacy sector
- Clinical Laboratories in the state of California. Platform of 20-60million in sales. Small labs with ebitda from 800k, 1m-5m.
- medical equipment/respiratory/mobility industry, and another focused more on behavioral health services
- We are seeking a company generating between 2 and 10 M EBITDA with scale-up potential, room for operational efficiencies and institutionalization. Preferably with operations in the Sun Belt Region of the United States
- Clinical practices (dental, O&P, IVF, etc.), healthcare technology and medical devices. 750K SDE minimum, 3M-7M target
- interested in the healthcare, technology, business services industries and in rental business models
- We are looking to acquire and operate a business with $1-5M EBITDA
- We're looking for multiple acquisitions in the healthcare industry for a roll up into our public company. We're hoping to eclipse $3bb in revenue worldwide within the next 4 years.
- Businesses in the biotech area.
- Home Health Agency, open to size.
- Nursing and Allied medical Staffing
- Medical practices in all of Florida $2m-$10m
- Ancillary Support Services, Behavioral Health Services, Healthcare Financial Services, Healthcare Provider, Home Health / Hospice, Medical Supply, Other, Pharmacy
- We are looking to purchase 10 + urgent cares, ideally in Texas to start with plans to expand nationally. We are looking for an EBITDA of 2M to 5M.
- Adult Mental Health, Child Pediatric Health
- We are a large Home Care agency located in NY. We are looking to expand to Florida, and Pennsylvania.
- DME companies who provide continuous glucose monitoring (CGM) systems.
|
|
The Strength of Healthcare M&A
Now and On The Horizon
|
|
What is driving all the M&A activities for privately held healthcare businesses through a global pandemic and beyond?
- Is it Availability of Capital?
- Is it Uncertainty of Rising Taxes?
- Is it the possibility of Higher Interest Rates?
This PWC article link and the slides below show the power of the current financial and debt markets driving buyer/investor M&A appetites. The amount of available capital in 2020 for mergers & acquisitions is unprecedented. This year the USA funding and stimulus spending amid the pandemic has been equally historic. While the results of the election may be uncertain, experts agree that there will be tax increases in the years ahead… no matter who wins the election. Future tax impacts could be egregious for capital gains and estate taxes as well. A similar uncertainty exists with interest rates which already are at historically low levels. With all of these factors, it is easy to understand how the M&A markets are being propelled and buyer/investor interests are growing.
For healthcare business owners, the growth and consolidation which has been increasing over the past few years, is accelerating. Corporate buyers and strategic private equity continue to seek strong, growing healthcare businesses and their appetites are increasing. It should also be noted that the buyer profiles have also changed with cross-modality and deep reaching synergies also driving opportunities.
|
|
Consolidation of healthcare services will also continue to improve outcomes and economic performance will be enhanced as we shift patient volumes to less costly care sites, and leverage technology across the continuum of care.
Exploring Strategic Options
There are many options to consider as the ultimate goal for the many years of hard work building and growing your company. For mature and profitable healthcare businesses today there are many strategic options to consider. These options include acquisitions, merger, divestiture, and recapitalization. Each of these options requires careful consideration to determine what is the best fit for the stakeholder’s goals for the business.
Should you consider a buyer or an investor? If your goal is to sell and ride off into the sunset, then your focus should be on a divestiture. If your interest is in taking chips off the table while continuing to grow the business over the next three to five years, then a recapitalization may be the best path for you. Each option has differing effects on valuation, the process and the pathway to a successful closing.
Exit strategy planning is one of the most overlooked – and most important aspects – of a business owner’s dream. You would not read all but the last chapter of a book… nor should you ignore the final chapter in your business ownership. Contact us today to discuss your strategic options.
|
|
We are wrapping up some new opportunities which will soon be available in market
The Paragon Ventures Private Client Group M&A Team
800-719-1555
|
|
Paragon Ventures LLC 800-719-1555 | www.paragonventures.com
|
|
|
|
|
|
|